AKAbdullah Khan

Abdullah Khan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdullah Khan has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Review on 3D Printing Filaments Used in Fused Deposition Modeling Method for Dermatological Preparations

    by Yong Li Chan, Riyanto Teguh Widodo, Long Chiau Ming, Abdullah Khan, Syed Atif Abbas, Ng Yen Ping, Zarif Mohamed Sofian, Mahibub Mahamadsa Kanakal

    Three-dimensional printing, particularly Fused Deposition Modeling (FDM), has revolutionized dermatological drug delivery by offering the ability to create personalized and precise drug formulations. This technology enables the design of customized drug delivery systems using a variety of polymers, such as Polylactic Acid (PLA), Polyvinyl Alcohol (PVA), Polyethylene Glycol (PEG), and Polycaprolactone (PCL), each with unique properties that enhance drug release, patient compliance, and treatment efficacy. This review analyzes these polymers in terms of their advantages, limitations, and suitability for dermatological applications. The ability to tailor these materials offers significant potential in overcoming treatment regimens. Additionally, the customization of three-dimensional-printed drug delivery systems provides a platform for creating patient-specific solutions that are more effective and adaptable to individual needs. Despite challenges such as moisture sensitivity and mechanical brittleness, the potential of FDM technology to improve dermatological treatments remains promising. The future of three-dimensional printing in dermatology lies in the integration of optimized materials and advanced printing techniques, which could further enhance patient-specific care and broaden the clinical applicability of these technologies in the pharmaceutical and biomedical sectors. By addressing these limitations and expanding material choices, FDM-based drug delivery systems have the potential to revolutionize the management of dermatological conditions, offering improved therapeutic outcomes and quality of life for patients.


  • Open Access

    Ayurvedic herbal formulations Haridra Khanda and Manjisthadi Kwath (brihat) in the management of allergic rhinitis: A pharmacological study

    by Rudranil Bhowmik, Adil Shaharyar, Mahibub Mahamadsa Kanakal, Arnab Sarkar, Syeda Ayesha Farhana, Shalam M. Hussain, Abdullah Khan, Pallab Mandal, S. Roshan, Achintya Mitra, et al.


  • Open Access

    Phaleria macrocarpa (Scheff.) Boerl. in Ethnopharmacology: Pharmacognosy, Safety, and Drug Development Perspectives

    by Anandarajagopal Kalusalingam, Kamaliah Kamal, Abdullah Khan, Bama Menon, Ching Siang Tan, Venkateshan Narayanan, Sattanathan Kumar, Khang Wen Goh, Kah Seng Lee, Jactty Chew, et al.

    Phaleria macrocarpa, a medicinal plant from the Thymelaceae family, is predominantly found in Malaysia and Indonesia. This review aims to comprehensively summarize the phytochemical, pharmacological, and toxicological aspects of P. macrocarpa, along with modern approaches and safety concerns. Data for the review were collected from various scientific databases and relevant literature on P. macrocarpa. The review discusses the plant's phytochemical composition and its diverse medicinal properties, including anti-inflammatory, antihypertensive, antidiabetic, antioxidant, antimicrobial, antipyretic, antiulcer, antiviral and anticancer activities. P. macrocarpa has also been used to treat various female health conditions. Additionally, combination therapies and advanced drug delivery systems such as nanoemulsion have been reviewed. These pharmacological activities are attributed to the plant's phytoconstituents. The review will be valuable for researchers involved in medicinal plant research and drug discovery, offering potential for use alongside modern therapeutic agents. However, clinical studies are essential to validate its therapeutic applications. Further research is required to develop standardized herbal pharmaceuticals from P. macrocarpa that are effective, safe, and meet regulatory standards for quality assurance.


  • Open Access

    Ex Vivo Antiplatelet and Thrombolytic Activity of Bioactive Fractions from the New-Fangled Stem Buds of Ficus religiosa L. with Simultaneous GC-MS Examination

    by Sunil Kumar, Muhammad Arif, Mehnaz Kamal, Talha Jawaid, Mohammed Moizuddin Khan, Beenish Mukhtar, Abdullah Khan, Saif Ahmed, Saud M. AlSanad, Osama A. Al-Khamees

    Different parts of Ficus religiosa are the common components of various traditional formulations for the treatment of several blood disorders. The new-fangled stem buds’ powder was extracted with 80% ethanol and successively fractionated by chloroform and methanol. Chloroform and methanol fractions of Ficus religiosa (CFFR and MFFR) were tested for antiplatelet, antithrombotic, thrombolytic, and antioxidant activity in ex vivo mode. The MFFR was particularly investigated for GC-MS and toxicity. The antiplatelet activity of the CFFR, MFFR, and standard drug aspirin at 50 μg/mL was 54.32%, 86.61%, and 87.57%, and a significant delay in clot formation was noted. CFFR at different concentrations did not show a significant effect on the delay of clot formation, antiplatelet, and free radical scavenging activity. The most possible marker compounds for antiplatelet and antioxidant activity identified by GC-MS in the MFFR are salicylate derivatives aromatic compounds such as benzeneacetaldehyde (7), phenylmalonic acid (13), and Salicylic acid (14), as well as Benzamides derivatives such as carbobenzyloxy-dl-norvaline (17), 3-acetoxy-2(1H)-pyridone (16), and 3-benzylhexahydropyrrolo [1,2-a] pyrazine-1,4-dione (35). A toxicity study of MFFR did not show any physical indications of toxicity and mortality up to 1500 mg/kg body weight and nontoxic up to 1000 mg/kg, which is promising for the treatment of atherothrombotic diseases.